3
Clinical Trials associated with Tolerogenic Dendritic Cells(Hospital Clínic de Barcelona) / Not yet recruitingPhase 1IIT Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients
The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.
Start Date01 May 2025 |
Sponsor / Collaborator- |
/ CompletedNot ApplicableIIT Immune intervention with tolerogenic dendritic cells in type 1 diabetes. A phase 1 safety study called D-sense - D-sense
Start Date09 Nov 2015 |
Sponsor / Collaborator- |
Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease
Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment.
100 Clinical Results associated with Tolerogenic Dendritic Cells(Hospital Clínic de Barcelona)
100 Translational Medicine associated with Tolerogenic Dendritic Cells(Hospital Clínic de Barcelona)
100 Patents (Medical) associated with Tolerogenic Dendritic Cells(Hospital Clínic de Barcelona)
100 Deals associated with Tolerogenic Dendritic Cells(Hospital Clínic de Barcelona)